Busulfan.txt Busulfan CLINICAL USE Chronic myeloid leukaemia Remission of polycythaemia vera Essential thrombocythaemia and myelofibrosis Conditioning before bone marrow transplantation DOSE IN NORMAL RENAL FUNCTION Oral: Chronic myeloid leukaemia: 60 mcg/kg daily (maximum 4 mg daily); maintenance: 0.5–2 mg daily Polycythaemia vera: 4–6 mg daily; maintenance: 2–3 mg daily Myelofibrosis: 2–4 mg daily IV infusion Conditioning before bone marrow transplantation: 0.8 mg/kg every 6 hours over 4 days for 16 doses PHARMACOKINETICS Molecular weight                           :246.3 %Protein binding                           :7–32 %Excreted unchanged in urine     : 1–2 Volume of distribution (L/kg)       :0.62–0.85 half-life – normal/ESRD (hrs)      :3/– DOSE IN RENAL IMPAIRMENT GFR (mL/MIN) 20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES CAPD                :Unknown dialysability. Dose as in normal renal function HD                     :Dialysed. Dose as in normal renal functionHDF/high flux   :Dialysed. Dose as in normal renal functionCAV/VVHD      :Unknown dialysability. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS Potentially hazardous interactions with other drugs Antibacterials: concentration increased by metronidazole Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis Antifungals: metabolism inhibited by itraconazole, monitor for signs of busulfan toxicity ADMINISTRATION Reconstition– Route Oral, IV infusion Rate of Administration Over 2 hours CommentsDilute the solution to 500 mcg/mL with sodium chloride or glucose 5%Give via a central venous catheter OTHER INFORMATION Can cause haemorrhagic cystitis Can cause an increase in creatinine and haematuria. Tags: post-by-auto-php Continue Reading Previous Previous post: Bleomycin.txtNext Next post: CYCLOTHYMIA.txt Related News sotalol hydrochloride.txt tazocin.txt